Lupin has launched Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, to market a generic equivalent of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, of Janssen Research and Development, LLC. Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of $112 million in the U.S. (IQVIA MAT August 2022).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
